Related by context. All words. (Click for frequent words.) 77 sustained virological response 75 virologic response 75 virologic failure 74 undetectable HCV RNA 73 peginterferon 73 SVR# 72 peginterferon alfa 2a 72 complete cytogenetic response 72 HBeAg seroconversion 71 rapid virologic response 71 ACR# response 71 CCyR 71 viral kinetics 71 Sustained Virological Response 71 ribavirin RBV 71 ribavirin therapy 71 ritonavir boosted 70 CIMZIA TM 70 Pegasys plus Copegus 70 virological failure 70 virological response 70 nitazoxanide 70 detectable HCV RNA 70 null responders 70 peg interferon 69 decitabine 69 complete cytogenetic 69 undetectable viral load 69 viral suppression 69 interferon ribavirin 69 tipranavir 69 adalimumab 69 pCR 69 FOLFOX4 69 PASI scores 69 Sustained virologic response 69 CR nPR 68 invasive aspergillosis 68 adefovir 68 pegylated interferon alfa 68 peginterferon alfa 2b 68 pegylated interferon 68 ACTEMRA TM 68 genotypic resistance 68 cytogenetic response 68 BARACLUDE ® 68 achieved sustained virologic 68 HCV SPRINT 68 standard chemotherapy regimen 68 relapsed MM 68 peg IFN 68 virologic responses 68 ABC/3TC 68 mcg albinterferon alfa 2b 68 APTIVUS r 68 chlorambucil 68 seroprotection 67 TDF FTC 67 achieved sustained virological 67 HCV RESPOND 2 67 PREZISTA r 67 mg kg dose 67 raltegravir 67 undetectable HBV DNA 67 plus ribavirin 67 virologic suppression 67 plus dexamethasone 67 pegylated interferon alpha 67 log# reduction 67 remission CR 67 NNRTI resistance 67 baseline HbA1c 67 entecavir 67 plus COPEGUS 67 alfa 2a 66 placebo dexamethasone 66 clodronate 66 CIMZIA ™ 66 iniparib 66 HIV RNA 66 seroconversion 66 boceprevir 66 Peg IFN 66 virologic 66 oral FTY# 66 abacavir lamivudine 66 protease inhibitor PI 66 PSA nadir 66 achieved ACR# 66 chronic HCV infection 66 plus methotrexate 66 ACR# responses 66 liver histology 66 platelet reactivity 66 undetectable viral 66 LEXIVA r 66 serum clusterin levels 66 steroid dexamethasone 66 tipranavir r 66 certolizumab 66 FOLFIRI 66 HCV RNA 66 cEVR 66 docetaxel chemotherapy 66 HbA1c levels 66 FOLFOX6 66 CIMZIA TM certolizumab pegol 66 #mg QD [001] 66 Sustained Virologic Response 66 mg QD 66 telaprevir dosed 66 Doxil ® 66 riociguat 65 interferon alfa 65 gout flares 65 undetectable hepatitis C 65 annualized relapse 65 HBeAg positive patients 65 tirofiban 65 fluvastatin 65 biochemical relapse 65 hepatitis C genotype 65 amoxicillin clavulanate 65 imatinib therapy 65 doripenem 65 recurrent VTE 65 cabazitaxel 65 dasatinib 65 recurrent glioblastoma multiforme 65 log# copies mL 65 pomalidomide 65 virological suppression 65 REYATAZ r 65 nab paclitaxel 65 nilotinib 65 serum HBV DNA 65 serum urate 65 mg/m2 dose 65 abiraterone acetate 65 plasma HCV RNA 65 VFEND 65 response CCyR 65 antiretroviral naive 65 mg TID 65 #mg dose [002] 65 clinically meaningful improvement 65 mg BID 65 PSADT 65 evaluable subjects 65 tolvaptan 65 Kaplan Meier analysis 65 sUA 65 experienced virologic failure 65 vicriviroc 65 low dose Iluvien 65 seropositive patients 65 octreotide LAR 65 tocilizumab 65 teriflunomide 65 FluCAM 65 oxycodone CR 65 lamivudine 65 ertapenem 65 HBV DNA levels 65 Virologic 65 PROMACTA 65 dosing cohorts 65 glycated hemoglobin levels 65 PegIFN RBV 64 tipranavir ritonavir 64 ibandronate 64 Crohn Disease Activity 64 microbiological eradication 64 infliximab 64 mycophenolate mofetil 64 posaconazole 64 peginterferon ribavirin 64 XELOX 64 Free Survival PFS 64 HCV genotype 1 64 LPV r 64 definite stent thrombosis 64 XIENCE V PROMUS Stent 64 A1c levels 64 colesevelam HCl 64 trastuzumab Herceptin ® 64 Bezielle 64 FOLFOX 64 imipenem 64 undetectable virus HCV 64 lopinavir r arm 64 mitoxantrone 64 receiving VICTRELIS 64 #mg BID [001] 64 interferon therapy 64 HBeAg negative 64 5-FU/LV 64 pegIFN 64 mRCC 64 Flu Cy 64 chemoradiotherapy 64 temsirolimus 64 CANCIDAS 64 hemoglobin A1c HbA1c 64 ribavirin USP 64 serum HCV RNA 64 antiviral efficacy 64 Aptivus ® 64 achieved CCyR 64 rFVIIa 64 INC# 64 comparator arm 64 lipid lowering therapy 64 HCV infected 64 FOLPI 64 postoperative chemotherapy 64 RGT arm 64 HCV genotype 64 HBeAg 64 severe neutropenia 64 intravenous bisphosphonates 64 NATRECOR R 64 piperacillin tazobactam 64 telbivudine 64 telaprevir 64 bosentan 64 heavily pretreated 64 adalimumab Humira 64 APTIVUS 64 zoledronic acid 64 tumor recurrence 64 clinically evaluable patients 64 dacarbazine 64 dose cohort 64 serum urate levels 64 Pegasys ® 64 MCyR 64 ULORIC 63 cilostazol 63 baminercept 63 dose cytarabine 63 INTELENCE 63 tolterodine ER 63 HBeAg negative patients 63 mapatumumab 63 atazanavir ritonavir 63 anthracycline taxane 63 CMV disease 63 tapentadol ER 63 CMV infection 63 dose dexamethasone 63 oral allopurinol 63 resected pancreatic cancer 63 progression TTP 63 hemoglobin A1c levels 63 copies mL 63 Dasatinib 63 HSCT 63 imatinib 63 undetectable viral loads 63 achieve sustained virologic 63 Traficet EN 63 tumor shrinkage 63 APTIVUS R 63 HBeAg positive 63 binary restenosis 63 insulin detemir 63 INCB# [001] 63 lumbar spine BMD 63 virologic response EVR 63 PEG IFN 63 recurrent genital herpes 63 paliperidone ER 63 morphometric vertebral fractures 63 lopinavir r 63 CLARITY study 63 interferon alfa 2b 63 oral diclofenac 63 peginterferon alpha 2a 63 Telbivudine 63 biochemical recurrence 63 CR CRu 63 Pegasys peginterferon alfa 2a 63 MAGE A3 ASCI 63 topotecan 63 HPV-#/# 63 NATRECOR ® 63 active comparator 63 DMARD 63 carboplatin paclitaxel 63 Engerix B 63 neutrophil counts 63 TMC# r 63 galiximab 63 virologically 63 methotrexate monotherapy 63 fosamprenavir 63 cART 63 ARB telmisartan 63 canakinumab 63 mucosal healing 63 DAPT 63 neurologic progression 63 prospectively defined 63 mg RDEA# 63 Solid Tumors criteria 63 mg dose 63 KRAS status 63 pegylated interferon alfa 2a 63 Copegus ribavirin 63 PRADAXA 63 invasive candidiasis 63 viral loads 63 EGFR TKI 63 R0 resection 63 oral ridaforolimus 63 rosuvastatin #mg 63 rapid virological response 63 serum phosphorous 63 visilizumab 63 bezafibrate 63 valacyclovir 63 viral load 63 bendamustine 63 azacitidine 63 AZT zidovudine Retrovir 63 radezolid 62 lamivudine refractory patients 62 HbA1C 62 ARCOXIA 62 μg dose 62 median PFS 62 lamivudine monotherapy 62 adjuvant radiation 62 adenoma recurrence 62 DAS# remission 62 gemcitabine carboplatin 62 HBV DNA 62 DAS# CRP 62 K ras mutations 62 interferon alfa 2a 62 EDSS scores 62 AGILECT R 62 ZOLINZA 62 mg ustekinumab 62 mcg dose 62 preoperative chemotherapy 62 tenofovir emtricitabine 62 antiretroviral naïve 62 NNRTIs 62 glatiramer acetate 62 pegylated interferon peg IFN 62 peginterferon alfa 62 Pegylated Interferon 62 mcg doses 62 Xelox 62 Median survival 62 Fludara 62 azathioprine 62 darunavir ritonavir 62 lumiliximab 62 Elitek 62 surrogate endpoint 62 prednisone prednisolone 62 ritonavir boosted atazanavir 62 SCH # 62 lenalidomide Revlimid R 62 endoscopic remission 62 Response Evaluation Criteria 62 idraparinux 62 OGTT 62 log# IU mL 62 Lupuzor ™ 62 chemoradiation therapy 62 locoregional recurrence 62 YERVOY 62 desvenlafaxine succinate 62 dexamethasone Decadron 62 idarubicin 62 timepoint 62 TORISEL 62 valopicitabine 62 candidemia 62 grade cervical intraepithelial 62 nucleoside naive 62 dapagliflozin plus 62 highly emetogenic 62 alteplase 62 free survival PFS 62 8mg/kg 62 alanine aminotransferase ALT 62 Peginterferon 62 Non inferiority 62 severe exacerbations 62 antihypertensive therapy 62 tamoxifen therapy 62 paricalcitol 62 complete remissions 62 Combination therapy 62 INFERGEN 62 doxorubicin docetaxel 62 achieved PASI 62 Index CDAI 62 eosinophilic asthma 62 chronic HCV 62 Merck boceprevir 62 H. pylori eradication 62 sitaxsentan 62 lopinavir 62 pegfilgrastim 62 Campath alemtuzumab 62 oral rivaroxaban 62 R# #mg BID 62 sunitinib 62 TNF antagonist 62 Teriflunomide 62 cediranib 62 DOXIL 62 etanercept 62 Peginterferon Alfa 2a 62 Raptiva r 62 daunorubicin 62 metastatic CRC 62 thalidomide Thalomid 62 coinfected 62 Folfox 62 olmesartan 62 ezetimibe simvastatin 62 liver metastasis 62 serum testosterone 62 receiving golimumab 62 vaginal progesterone gel 62 ALND 62 mcg Albuferon 62 VELCADE melphalan 62 acute gout flares 62 Boceprevir 62 PEG Intron 62 Gleevec imatinib 62 secondary efficacy endpoint 62 curative resection 62 TMC# [001] 62 Reverset 62 VICTRELIS 62 mutated KRAS 62 IRESSA 62 TYGACIL 62 antibody titer 62 RRMS patients 62 Pemetrexed 62 febrile neutropenia 62 urate lowering therapy 62 olaparib 62 COMBIVIR 62 glycated hemoglobin HbA1c 62 telaprevir VX 62 QTcF 62 sorafenib tablets 62 ATACAND 62 CDI recurrence 62 ACZ# 62 hepatic fibrosis 62 TEAEs 62 ILLUMINATE 61 PEGINTRON TM 61 angiographic outcomes 61 intensive statin therapy 61 sorafenib Nexavar 61 dalteparin 61 elvitegravir 61 endometrial hyperplasia 61 PEG Interferon alfa 61 Thal Dex 61 radiographic progression 61 divalproex sodium 61 evaluating tivozanib 61 neoadjuvant chemotherapy 61 q8h 61 low dose cytarabine 61 treatment naive genotype 61 elotuzumab 61 MACCE 61 elagolix 61 Psoriasis Area 61 ISENTRESS 61 hematologic toxicity 61 forodesine 61 goserelin 61 poor metabolizers 61 ximelagatran 61 #mg/day [002] 61 FOLFIRINOX 61 adjunctive placebo 61 plasma uric acid 61 spontaneous bowel movements 61 ribavirin 61 chemoradiation 61 achieved statistical significance 61 dosing cohort 61 salmeterol fluticasone 61 low dose ritonavir 61 pyrazinamide 61 ug dose 61 Jevtana 61 RECIST Response Evaluation Criteria 61 TMP SMX 61 recurrent GBM 61 FIRMAGON 61 Ceplene/IL-2 61 COPAXONE R 61 CTAP# Capsules 61 alpha 2a 61 androgen deprivation 61 icatibant 61 HIV HCV coinfected 61 acute STEMI 61 AVODART 61 IV bisphosphonates 61 mesalamine granules 61 CRp 61 axitinib 61 elevated ALT 61 administered subcutaneously 61 receiving prophylactic anticoagulation 61 refractory gout 61 Roche Pegasys 61 ACUITY trial 61 CsA 61 NLX P# 61 cangrelor 61 A1C levels 61 NNRTI 61 HbA 1c levels 61 amprenavir 61 enfuvirtide 61 IELT 61 debulking surgery 61 pegylated interferon alfa 2b 61 standard chemotherapy regimens 61 renal toxicity 61 metastatic castration resistant 61 anastrozole 61 XGEVA 61 cidofovir 61 Velcade bortezomib 61 β blockers 61 BENICAR HCT 61 KRAS mutations occur 61 moderate renal impairment 61 Naive Patients 61 anagrelide 61 metastatic RCC 61 azacytidine 61 sipuleucel T 61 STRIDE PD 61 nucleotide analog 61 trastuzumab 61 co trimoxazole 61 Torisel 61 DFMO 61 NRTI 61 low expressors 61 Hepsera 61 pyridostigmine 61 tenofovir FTC 61 allogeneic HSCT 61 ALT normalization 61 caspofungin 61 enoximone 61 metastatic renal cell carcinoma 61 irinotecan chemotherapy 61 nicardipine 61 ELOXATIN 61 HER2 expression 61 briakinumab 61 FOLFOX4 alone 61 teriparatide 61 levosimendan 61 prior chemotherapy regimens 61 aprepitant 61 RAPAFLO 61 darapladib 61 anemia hemoglobin 61 PREZISTA ritonavir 61 belimumab 61 IFN α 61 MYCAMINE 61 CIN3 61 REYATAZ R 61 dosing regimens 61 5 Fluorouracil 61 Hb A1C 61 HBsAg 61 methotrexate therapy 61 esophageal candidiasis 61 Taxotere ® 61 COPD exacerbations 61 FTC TDF 61 Natalizumab 61 eptifibatide 61 relapsing MS 61 PEG INTRON 61 Epivir 61 evaluable patients 61 mcg BID 61 Pegylated Liposomal Doxorubicin 61 T#I [002] 61 tigecycline 61 COPEGUS 61 BEACOPP 61 efavirenz Sustiva 61 pazopanib 61 docetaxel Taxotere ® 61 PegIntron 61 talabostat 61 CCR5 antagonist 61 SCIg 61 postoperative mortality 61 serologically active patients 61 nephrotoxicity 61 Adalimumab 61 -#.# log# 61 insulin degludec 61 colorectal liver metastases 61 advanced adenomas 61 anti leukemic 61 response pCR 61 lapatinib Tykerb 61 CoFactor 61 relapsed SCLC 61 CHOP chemotherapy 61 edifoligide 61 KRAS mutation 61 ALT flares 61 boosted protease inhibitor 61 dose regimens 61 TAXUS Stent 61 sargramostim 61 micafungin 61 discontinuations due 61 stavudine d4T 61 HAART regimen 61 Follicular Lymphoma 61 FOLPI regimen 61 PEGylated interferon beta 1a 61 glycosylated hemoglobin HbA1c 61 MoxDuo TM IR 61 #mg QD [002] 61 tamsulosin 61 ritonavir boosted lopinavir 61 dose cohorts 61 Neoadjuvant 61 corticosteroid therapy 61 monotherapy 61 FROVA 61 pegylated liposomal doxorubicin 61 EXJADE 61 eltrombopag 61 viremia 61 oral antidiabetic medication 61 serum potassium 61 gefitinib Iressa 61 thromboembolic events 61 nonresponders 61 non metastatic osteosarcoma 61 imatinib Gleevec 61 estramustine 61 log# 61 peginterferon alfa 2a Pegasys 61 achieving sustained virologic 61 Decitabine 61 patients evaluable 61 vandetanib 61 maximally tolerated dose 61 combination antiretroviral therapy 61 Lucentis monotherapy 60 biologic DMARD 60 darunavir r 60 custirsen 60 fluticasone salmeterol 60 abiraterone 60 gemcitabine chemotherapy 60 postmenopausal osteoporotic women 60 Sprycel dasatinib 60 dose melphalan 60 leukemia AML 60 leukemia ALL 60 STELARA ® 60 Scale EDSS 60 oral vancomycin 60 gemifloxacin 60 dose atorvastatin 60 zidovudine lamivudine 60 ARCALYST ® 60 elacytarabine 60 eplerenone 60 noninferiority 60 Subgroup analysis 60 statistical significance p 60 dasatinib Sprycel 60 nadolol 60 angiographic restenosis 60 celgosivir 60 IU mL 60 Betaferon ® 60 VIRAMUNE 60 Navelbine ® 60 disease progression 60 pentoxifylline 60 pegylated alpha interferon 60 tiotropium 60 MYDICAR ® 60 pegylated interferons 60 neoadjuvant therapy 60 NEVO ™ 60 #mg/day [001] 60 rizatriptan 60 CCR5 tropic HIV 60 #mg q8h 60 4mg/kg 60 secondary endpoint 60 infliximab monotherapy 60 Solid Tumors 60 certolizumab pegol 60 Hydroxyurea 60 alkylating agent 60 HAART regimens 60 bisphosphonate therapy 60 refractory chronic lymphocytic 60 omega interferon 60 HCV infection 60 losartan 60 iclaprim 60 Femara letrozole 60 trimethoprim sulfamethoxazole 60 chronic HBV 60 clomipramine 60 linezolid 60 hsCRP levels 60 KRAS wild 60 metastatic hormone refractory 60 chronic HCV genotype 60 ZYVOX 60 superficial bladder cancer 60 erlotinib Tarceva ® 60 virus HCV protease inhibitor 60 pramlintide 60 PREZISTA rtv 60 rt PA 60 CD4 + cell 60 STELARA 60 5-fluorouracil/leucovorin 60 azilsartan medoxomil 60 atorvastatin #mg 60 Chronic Hepatitis C 60 NRTI backbone 60 YMRS 60 plus prednisone 60 dosing intervals 60 Trastuzumab 60 naïve HCV 60 Kaplan Meier estimates 60 NPH insulin 60 odanacatib 60 serum phosphate 60 comparator PI r 60 treatment naïve genotype 60 NAbs 60 minimally symptomatic 60 stage IIIB 60 clopidogrel Plavix 60 IOP lowering 60 stage IIIb IV 60 tamoxifen Nolvadex ® 60 COPAXONE ® 60 heavily pretreated patients 60 Ribavirin 60 relapsing multiple sclerosis 60 FluCAM arm 60 atazanavir 60 Omacetaxine 60 ER CHOP 60 oral methylnaltrexone 60 baseline LDH 60 Mylotarg 60 titrated glipizide 60 concomitant antibiotics 60 neoadjuvant treatment 60 postdose 60 neoadjuvant 60 candesartan cilexetil 60 #mg dose [001] 60 LY# [003] 60 dose cyclophosphamide 60 Altastaph 60 unfractionated heparin 60 empiric therapy 60 Dose escalation 60 weekly subcutaneous injections 60 HCV Genotype 60 baseline A1C 60 haematologic 60 APTIVUS ritonavir 60 seroconverted 60 PREZISTA r arm 60 cisplatin gemcitabine 60 solifenacin 60 Phase 2a trial 60 liver biopsies 60 TNF alpha antagonist 60 Scale EDSS score 60 recurrent venous thromboembolism 60 pertuzumab 60 regorafenib 60 KRAS mutant tumors 60 DASISION 60 rindopepimut 60 anthracycline containing 60 cobicistat 60 dose clopidogrel 60 interferon gamma 1b 60 degarelix 60 serum phosphorus 60 GOUT 60 Tekamlo 60 CDAI score 60 serum uric acid 60 antiangiogenic therapy 60 RLAI 60 Cytoxan 60 cetuximab Erbitux 60 HER2 positive metastatic breast 60 tumor progression TTP 60 Hycamtin ® 60 abatacept 60 VIDAZA 60 Epratuzumab 60 LymphoStat B 60 efavirenz EFV 60 IFN beta 60 mCRC patients 60 unresectable stage 60 dosage regimens 60 HAART 60 TPV r 60 Virologic failure 60 nonnucleoside reverse transcriptase inhibitors 60 bicalutamide 60 PegIFN 60 unresectable tumors 60 chlamydial infection 60 androgen suppression 60 FDA defined valvulopathy 60 Herceptin trastuzumab 60 placebo 60 ancrod 60 Treatment Naive Patients 60 ipsilateral stroke 60 dutasteride 60 interferon beta therapy 60 indinavir 60 ACR# [002] 60 mcg kg 60 plus MTX 60 ispinesib administered 60 neostigmine 60 confirmed CCyR 60 postprocedure 60 antibiotic rifaximin 60 CINQUIL 60 ruboxistaurin 60 abnormal cytology 60 ivabradine 60 antiviral therapy 60 DEB# 60 median survivals 60 secondary efficacy endpoints 60 weekly CSBMs 60 recurrent glioma 60 phase IIb study 60 Events MACE 60 daily Infergen 60 corticosteroid dose 60 hypofractionated radiation 60 Vfend 60 PRADAXA #mg 60 serum creatinine levels 60 TroVax ® 60 gefitinib 60 refractory NSCLC 60 paclitaxel cisplatin 60 hyperphenylalaninemia HPA due 60 DMARDs 60 symptomatic VTE 60 lymphocyte count 60 cervical intraepithelial neoplasia 60 Q#IR 60 GSK# [001] 60 partial remissions 60 candesartan 60 lipid lowering drugs 60 DAS# [002] 60 rilpivirine 60 AA Amyloidosis 60 flutamide 60 Serious adverse reactions 60 Tipranavir 60 taxotere 60 HER2 overexpression 60 VAPRISOL 60 Cloretazine 60 nadroparin 60 DU #b 60 uric acid lowering 60 RECIST criteria 59 Montgomery Asberg Depression 59 ceftriaxone 59 fulvestrant 59 SPRYCEL ® 59 operable breast cancer 59 bevacizumab Avastin 59 Pharmacokinetic parameters 59 Darunavir 59 antiandrogen 59 Subgroup analyzes 59 BEXXAR Therapeutic Regimen 59 fasting plasma glucose 59 hour bronchodilation 59 iniparib BSI 59 Viramidine 59 Bevacizumab 59 cardiovascular calcification 59 specific antigen PSA 59 Phenoptin 59 ramipril 59 Viread Emtriva 59 apremilast 59 Amrubicin 59 intravenous cyclophosphamide 59 venous thromboembolic events 59 iloprost 59 viral kinetic 59 Lamictal XR 59 AVADO 59 CD4 cell 59 ceftazidime 59 Imatinib 59 bortezomib 59 peginterferon alfa 2a #KD 59 chemotherapy gemcitabine 59 REYATAZ r arm 59 Northera 59 Platinol ® cisplatin 59 CIPN 59 COPEGUS ribavirin 59 enalapril 59 Ishak fibrosis score 59 Telaprevir 59 T2DM 59 completely resected 59 induction regimen 59 Median PFS 59 vincristine doxorubicin 59 blood phenylalanine Phe 59 NMIBC 59 Tarceva TM 59 leukopenia 59 pimecrolimus 59 metastatic malignant 59 underwent resection 59 Hormone Refractory Prostate Cancer 59 delafloxacin 59 trastuzumab Herceptin R 59 adriamycin 59 Zevalin consolidation 59 achieve sustained virological 59 inecalcitol 59 LTBI 59 gemcitabine Gemzar 59 tolerability 59 ToGA 59 antimicrobial prophylaxis 59 enzastaurin 59 sorafenib 59 DAS# scores 59 noninferior 59 null responder HCV 59 allogeneic SCT 59 Nilotinib 59 unfractionated heparin UFH 59 limiting toxicity 59 intravenous dosing 59 BRAF inhibitor 59 relapsed ovarian cancer 59 aflibercept 59 timepoints 59 rituximab 59 relapsers 59 potent antiretroviral therapy